Profile data is unavailable for this security.
About the company
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.
- Revenue in USD (TTM)0.00
- Net income in USD-197.55m
- Incorporated2007
- Employees142.00
- LocationKura Oncology Inc12730 HIGH BLUFF DRIVE, SUITE 400SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 500-8800
- Fax+1 (302) 655-5049
- Websitehttps://www.kuraoncology.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Entrada Therapeutics Inc | 215.23m | 54.95m | 675.43m | 177.00 | 11.32 | 1.60 | 11.55 | 3.14 | 1.59 | 1.59 | 5.97 | 11.30 | 0.4141 | -- | 56.43 | 1,353,660.00 | 10.57 | -- | 13.68 | -- | -- | -- | 25.53 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
| Cullinan Therapeutics Inc | 0.00 | -143.54m | 711.54m | 85.00 | -- | 1.13 | -- | -- | -2.88 | -2.88 | 0.00 | 10.80 | 0.00 | -- | -- | 0.00 | -25.35 | -12.37 | -26.45 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
| Oruka Therapeutics Inc | 0.00 | -7.20m | 717.47m | 4.00 | -- | 0.7608 | -- | -- | -5.97 | -5.97 | 0.00 | 26.94 | 0.00 | -- | -- | 0.00 | -19.22 | -27.78 | -19.99 | -29.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 46.21 | -- | -- | -- |
| CARGO Therapeutics Inc | 0.00 | -154.14m | 722.08m | 116.00 | -- | 1.80 | -- | -- | -3.43 | -3.43 | 0.00 | 8.72 | 0.00 | -- | -- | 0.00 | -57.80 | -- | -65.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| Erasca Inc | 0.00 | -159.12m | 734.51m | 126.00 | -- | 1.63 | -- | -- | -0.8294 | -0.8294 | 0.00 | 1.59 | 0.00 | -- | -- | 0.00 | -33.56 | -- | -35.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.50 | -- | -- | -- |
| Replimune Group Inc | 0.00 | -213.02m | 754.95m | 331.00 | -- | 1.98 | -- | -- | -3.05 | -3.05 | 0.00 | 5.58 | 0.00 | -- | -- | 0.00 | -40.17 | -29.08 | -43.61 | -30.56 | -- | -- | -- | -- | -- | -- | 0.1577 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
| Anavex Life Sciences Corp | 0.00 | -41.53m | 764.86m | 40.00 | -- | 5.89 | -- | -- | -0.5012 | -0.5012 | 0.00 | 1.53 | 0.00 | -- | -- | 0.00 | -27.75 | -40.04 | -30.03 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
| Prothena Corporation PLC | 133.35m | -131.83m | 776.59m | 173.00 | -- | 1.45 | -- | 5.82 | -2.48 | -2.48 | 2.47 | 9.93 | 0.1987 | -- | 51.70 | 770,809.30 | -19.64 | -14.20 | -21.22 | -15.11 | -- | -- | -98.86 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
| Relay Therapeutics Inc | 10.01m | -345.20m | 776.66m | 294.00 | -- | 0.9231 | -- | 77.62 | -2.61 | -2.61 | 0.076 | 5.03 | 0.0109 | -- | -- | 30,978.33 | -37.58 | -28.55 | -39.69 | -29.54 | -- | -- | -3,449.92 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Tyra Biosciences Inc | 0.00 | -83.74m | 777.26m | 49.00 | -- | 2.24 | -- | -- | -1.61 | -1.61 | 0.00 | 6.85 | 0.00 | -- | -- | 0.00 | -27.06 | -- | -28.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
| Kura Oncology Inc | 0.00 | -197.55m | 782.30m | 142.00 | -- | 1.85 | -- | -- | -2.36 | -2.36 | 0.00 | 5.45 | 0.00 | -- | -- | 0.00 | -41.48 | -26.04 | -44.66 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0219 | -- | -- | -- | -12.36 | -- | -- | -- |
| AbCellera Biologics Inc | 32.96m | -175.80m | 803.40m | 586.00 | -- | 0.7337 | -- | 24.37 | -0.5999 | -0.5999 | 0.1125 | 3.71 | 0.0227 | -- | 0.958 | 56,250.85 | -12.10 | 6.08 | -12.95 | 6.67 | -- | -- | -533.32 | 24.69 | -- | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
| Capricor Therapeutics Inc | 23.23m | -34.11m | 808.91m | 101.00 | -- | 10.51 | -- | 34.82 | -1.06 | -1.06 | 0.7316 | 1.69 | 0.3571 | -- | 48.53 | 229,980.70 | -52.44 | -54.12 | -88.95 | -75.13 | -- | -- | -146.86 | -316.25 | -- | -- | 0.0471 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Rapport Therapeutics Inc | -100.00bn | -100.00bn | 823.70m | 58.00 | -- | 2.55 | -- | -- | -- | -- | -- | 8.83 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -226.57 | -- | -- | -- |
| Bicara Therapeutics Inc | -100.00bn | -100.00bn | 870.14m | 32.00 | -- | 1.90 | -- | -- | -- | -- | -- | 9.37 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -37.36 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Kura Oncology Inc's reporting currency: US Dollar USD
55.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Suvretta Capital Management LLCas of 30 Sep 2024 | 7.65m | 9.99% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 5.88m | 7.67% |
| EcoR1 Capital, LLCas of 30 Sep 2024 | 5.81m | 7.58% |
| Paradigm BioCapital Advisors LPas of 30 Sep 2024 | 4.33m | 5.65% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 4.02m | 5.24% |
| Avoro Capital Advisor LLCas of 30 Sep 2024 | 3.54m | 4.62% |
| BVF Partners LPas of 30 Sep 2024 | 3.37m | 4.40% |
| Holocene Advisors, LPas of 30 Sep 2024 | 2.69m | 3.51% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.67m | 3.48% |
| Armistice Capital LLCas of 30 Sep 2024 | 2.66m | 3.47% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
